Eli Lilly (LLY)
799.57
+0.00 (0.00%)
NYSE · Last Trade: Oct 22nd, 6:29 AM EDT
The rapid growth rates of recent years aren't guaranteed to continue.
Via The Motley Fool · October 22, 2025
Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains.
Via MarketBeat · October 21, 2025
Don't try to catch a falling surgical knife.
Via The Motley Fool · October 21, 2025
The tides continue to change in Eli Lilly's favor in the GLP-1 space.
Via The Motley Fool · October 21, 2025
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Via StockStory · October 21, 2025
Via Benzinga · October 20, 2025
As the financial markets gear up for the week commencing Monday, October 20, 2025, investors are keenly attuned to the insights of CNBC's Jim Cramer, a vocal and influential voice in the stock market. While a precise, real-time "Top 10" list from Cramer for this specific Monday is not publicly
Via MarketMinute · October 20, 2025
The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.
Via Investor's Business Daily · October 20, 2025
These companies are jockeying for position in a potential $150 billion market opportunity.
Via The Motley Fool · October 20, 2025
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Via StockStory · October 20, 2025
Via The Motley Fool · October 19, 2025
Via The Motley Fool · October 19, 2025
Via The Motley Fool · October 19, 2025
These two high-quality stocks can deliver impressive returns in the long run.
Via The Motley Fool · October 19, 2025
Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.
Via Benzinga · October 19, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · October 18, 2025
The Vanguard S&P 500 Growth ETF typically outperforms the S&P 500 over the long term.
Via The Motley Fool · October 18, 2025
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.
Via Benzinga · October 17, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill · October 17, 2025
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro.
Via StockStory · October 17, 2025
Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...
Via Benzinga · October 17, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · October 17, 2025
Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs.
Via Investor's Business Daily · October 17, 2025
The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently, pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) saw their shares plummet following a new round of
Via MarketMinute · October 17, 2025
Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.
Via Benzinga · October 17, 2025